CA2740010A1 - Bacteriophage preparation and use - Google Patents

Bacteriophage preparation and use Download PDF

Info

Publication number
CA2740010A1
CA2740010A1 CA2740010A CA2740010A CA2740010A1 CA 2740010 A1 CA2740010 A1 CA 2740010A1 CA 2740010 A CA2740010 A CA 2740010A CA 2740010 A CA2740010 A CA 2740010A CA 2740010 A1 CA2740010 A1 CA 2740010A1
Authority
CA
Canada
Prior art keywords
bacteriophage
bacteriophage preparation
preparation according
species
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2740010A
Other languages
French (fr)
Inventor
Gabriele Ruppert-Seipp
Neithard Dahlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovations Transfer Uphoff GmbH and Co KG
Original Assignee
Innovations Transfer Uphoff GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovations Transfer Uphoff GmbH and Co KG filed Critical Innovations Transfer Uphoff GmbH and Co KG
Publication of CA2740010A1 publication Critical patent/CA2740010A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Mycology (AREA)
  • Materials Engineering (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)
  • Pest Control & Pesticides (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a bacteriophage preparation having at least one bacteriophage in alkaline buffer solution, said bacteriophage being specifically effective against at least one bacterial strain, in combination with at least one surface-active agent that is preferably a polyhexamethyl biguanide (polyhexanide) stabilized in an alkaline range between pH 7.5 and pH 9Ø
The invention further relates to the use of such a bacteriophage preparation for the production of a pharmaceutical, particularly for therapeutic, preventative, and disinfecting antibacterial use. Finally, the invention also relates to a disinfection method using the bacteriophage preparation together with low-frequency ultrasound.

Claims (21)

1. A bacteriophage preparation for the treatment of colonizations caused by bacteria (contaminations, invasions, infections, and infectious diseases), characterized in that the preparation has at least one bacteriophage specifically effective against at least one bacterial strain in an alkaline buffer solution in combination with at least one surface-active agent.
2. The bacteriophage preparation according to claim 1, characterized in that the bacteriophage is lytically active against at least one bacterium selected from among Staphylococcus species, Pseudomonas species, Streptococcus species, Enterococcus species, Enterobacter species, Klebsiella species, Proteus species, Listeria species, and Salmonella species.
3. The bacteriophage preparation according to any one of the preceding claims, characterized in that the surface-active agent is selected from the group consisting of anionic or cationic surfactants, alcohols, enzymes, alginates, disinfectants, antiseptic agents or preservatives, or combinations thereof.
4. The bacteriophage preparation according to claim 3, characterized in that the surface-active agent is polyhexamethyl biguanide (polyhexanide).
5. The bacteriophage preparation according to claim 4, characterized in that the pH of the bacteriophage preparation is stabilized by at least one buffering salt to an alkaline range between pH 7.5 and pH 9Ø
6. The bacteriophage preparation according to any one of the preceding claims, characterized in that at least one surface-active agent is present in a concentration of 0.000001 to 20.0%
by weight, based on the entire bacteriophage preparation.
7. The bacteriophage preparation according to claim 1, characterized in that the preparation is present as a solution or suspension.
8. The bacteriophage preparation according to claim 1, characterized in that the preparation is present in gel form.
9. The bacteriophage preparation according to claim 8, characterized in that the preparation comprises glycerol or a polymer selected from the group consisting of derivatives of cellulose acetate and polymers of acrylic acid.
10. The bacteriophage preparation according to claim 9, characterized in that glycerol is present in a concentration of 1.0 to 10.0% by weight, based on the entire bacteriophage pool.
11. The bacteriophage preparation according to claim 10, characterized in that the polymer is present in a concentration of 0.1 to 10.0% by weight, based on the entire bacteriophage pool.
12. The bacteriophage preparation according to claim 1, characterized in that the preparation is present in textile fibers or synthetic fibers, or as a bulk material.
13. Use of a bacteriophage preparation according to any one of the preceding claims for producing a medication for therapeutic or preventive antibacterial use.
14. The use according to claim 13 for application in wounds and wound areas.
15. The use according to claim 13 for application in the nose-throat area.
16. The use according to claim 13 for application in the skin and mucous membrane area.
17. The use according to claim 13 for application in the urogenital area.
18. The use according to claim 13 for application in the eye area.
19. The use of a bacteriophage preparation according to any one of the preceding claims for the production of a disinfectant for antibacterial applications.
20. A disinfection method characterized by the application of the bacteriophage preparation according to any one of claims 1-11 with low-frequency ultrasound with a frequency range < 120 kHz and an output power of 0.05-1.5 W/cm2.
21. The disinfection method according to claim 19, characterized in that the bacteriophage preparation is heated before application to a temperature between 22°C
and 45°C.
CA2740010A 2008-01-18 2009-01-16 Bacteriophage preparation and use Abandoned CA2740010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008005193.4 2008-01-18
DE102008005193A DE102008005193A1 (en) 2008-01-18 2008-01-18 Bacteriophage preparation and use
PCT/EP2009/000249 WO2009090082A2 (en) 2008-01-18 2009-01-16 Bacteriophage preparation and use

Publications (1)

Publication Number Publication Date
CA2740010A1 true CA2740010A1 (en) 2009-07-23

Family

ID=40785905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2740010A Abandoned CA2740010A1 (en) 2008-01-18 2009-01-16 Bacteriophage preparation and use

Country Status (6)

Country Link
US (1) US20100291041A1 (en)
EP (1) EP2234497A2 (en)
JP (1) JP2011509964A (en)
CA (1) CA2740010A1 (en)
DE (1) DE102008005193A1 (en)
WO (1) WO2009090082A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2815652A2 (en) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Method for the decontamination of bacteriological impurities
CN112646785A (en) * 2020-12-30 2021-04-13 瑞科盟(青岛)生物工程有限公司 High-temperature-resistant virulent proteobacterium bacteriophage RDP-SA-20018 and application thereof
RU2772295C1 (en) * 2021-12-06 2022-05-18 Зураб Суликоевич Хабадзе Method for prevention of alveolitis of jaw

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010212270B2 (en) * 2009-08-12 2015-02-19 Buddhist Tzu Chi Medical Foundation Disinfectant composition comprising phage
DE102009049505A1 (en) * 2009-10-15 2011-04-21 Schülke & Mayr GmbH Disinfection procedure with simultaneous ultrasound treatment
DE102012007212A1 (en) 2012-04-11 2013-10-17 Merz Pharma Gmbh & Co. Kgaa Preparation for topical application to mucous membranes with polyhexanide as active ingredient
AU2015241439B2 (en) 2014-03-31 2018-11-08 Kimberly-Clark Worldwide, Inc. Self-regenerating antimicrobial composition and method of use
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
CN113699121B (en) * 2021-09-03 2024-05-03 青岛农业大学 Method for improving titer of T4 phage by cooperation of high-voltage electrostatic field, 1, 3-diglyceride and collagen peptide
RS67430B1 (en) * 2022-07-08 2025-12-31 Phatec Gmbh Hydroxyethycellulose gel compositions comprising bacteriophages

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918983D0 (en) 1989-08-21 1989-10-04 Unilever Plc Composition for hygiene purposes
DE59406509D1 (en) * 1993-05-26 1998-08-27 Fresenius Ag ANTI-INFECTIVE
WO1995001154A1 (en) * 1993-07-01 1995-01-12 Unilever N.V. Oral care compositions
EP0854933B1 (en) * 1995-09-07 2003-05-07 Novozymes A/S Phage display for detergent enzyme activity
EP1041141B1 (en) * 1999-03-30 2006-02-08 Council Of Scientific And Industrial Research A novel bacteriophage, a process for the isolation thereof and a universal growth medium useful in the process thereof
AU2001229342A1 (en) * 2000-01-11 2001-07-24 Intralytix, Inc. Method for produce sanitation using bacteriophages
US20040208853A1 (en) * 2000-01-11 2004-10-21 Intralytix, Inc. Method and device for sanitation using bacteriophages
DE10012026B4 (en) 2000-03-11 2004-01-08 Prontomed Gmbh Using a gel
US20020001590A1 (en) 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
US20070196496A1 (en) * 2002-04-16 2007-08-23 Michael Farber Delivery systems for functional ingredients

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2815652A2 (en) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Method for the decontamination of bacteriological impurities
DE102013106455A1 (en) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Method for decontamination of bacteriological contaminants
CN112646785A (en) * 2020-12-30 2021-04-13 瑞科盟(青岛)生物工程有限公司 High-temperature-resistant virulent proteobacterium bacteriophage RDP-SA-20018 and application thereof
RU2772295C1 (en) * 2021-12-06 2022-05-18 Зураб Суликоевич Хабадзе Method for prevention of alveolitis of jaw

Also Published As

Publication number Publication date
US20100291041A1 (en) 2010-11-18
DE102008005193A1 (en) 2009-07-23
WO2009090082A3 (en) 2010-07-15
WO2009090082A2 (en) 2009-07-23
EP2234497A2 (en) 2010-10-06
JP2011509964A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
JP7486557B2 (en) Semi-solid composition for preventing bacterial contamination - Patents.com
US20020182262A1 (en) Super-oxidized water, preparation and use thereof as sterilizers and medicaments
US9314028B2 (en) Compositions comprising a germinant and an antimicrobial agent
US20100291041A1 (en) Bacteriophage preparation and use
CN102329703A (en) Antibacterial soap and preparation method thereof
CN105126107A (en) Liquid wound dressing
US20200121582A1 (en) Ecofriendly Biofilm-Disrupting Antimicrobial Formulations, Their Development, and Their Uses
CN106291969A (en) A kind of antibacterial spectacle-frame and preparation method thereof
Goldade et al. Antimicrobial fibers for textile clothing and medicine: current state
US20150282487A1 (en) Complex and use thereof
US20240148932A1 (en) Wound dressing with preventive biofilm additive
CN112897194A (en) Production method of degradable hypochlorous acid disinfection wet tissue
CN102461499B (en) Disinfector for remains and preparation method thereof
JP4679854B2 (en) Sterilized bamboo fiber gauze
Nagoba et al. Boric acid-could it be a potential topical antiseptic agent?
CA2184813C (en) Wound disinfection and repair
CN101716061A (en) Sterilization and pasteurization towelette and preparation method thereof
Percival et al. 11 Antimicrobial
JP2006089473A (en) Alkaline bactericide
TWM331532U (en) Nano silver sock with disinfecting and deodorizing effect

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150116